Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03625557 · ClinicalTrials.gov registry record
Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records
A clinical trial, sponsored by Guardant Health.
- Completed
- Registry status
- 30
- Enrollment target
NCT03625557: Completed study, sponsored by Guardant Health.
NCT03625557 is a clinical trial that has completed, run by Guardant Health. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03625557 has completed, sponsored by Guardant Health.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
To document the clinical outcomes of cancer patients who received the Guardant360® test and agree to share their records with Guardant Health.
Primary Outcome
Portion of patients with tumors that are found to have complete or partial response
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2020-04-16 |
What the finished NCT03625557 record still lists
NCT03625557 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03625557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03625557 about?
NCT03625557 is a clinical study titled "Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records". To document the clinical outcomes of cancer patients who received the Guardant360® test and agree to share their records with Guardant Health.
What is the current status of trial NCT03625557?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2019-04-30. Estimated completion is 2020-04-16.
Who is sponsoring clinical trial NCT03625557?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI